Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Huntington's disease (HD) is a disease of the basal ganglia which results in a major loss of the striatal GABAergic medium spiny neurons containing enkephalin and substance P. These neurons project principally to the globus pallidus (GP) and substantia nigra pars reticulata (SNr). Both GABA(A) and GABA(B) receptors are localised postsynaptically on neurons in the GP and SNr, and cannabinoid (CB(1)) receptors are localised presynaptically on the axon terminals of the medium spiny projection neurons in the GP and SNr. The aims of this project were to investigate the changes in the distribution of CB(1), GABA(A), and GABA(B) receptor subunits, as well as enkephalin and substance P in the GP in the HD brain compared to the normal brain. The results of this study have shown firstly, that in the HD brain there is a dramatic loss of enkephalin and CB(1) receptor immunoreactivity (IR) in the external segment of the globus pallidus (GPe) and a major loss of substance P and CB(1) receptor-IR from the internal segment of the globus pallidus (GPi). Secondly, the degeneration of these striatal efferent neurons results in the upregulation of the various subunits of both GABA(A) (alpha(1), beta(2,3) and gamma(2)) and GABA(B) (R(1)) receptors in the GP in HD. Detailed double labelling confocal microscopy studies show that in HD the increased GABA(A) and GABA(B) receptor-IR is distributed not just in punctate "synaptic" regions, but throughout all dendritic and somal membranes of pallidal neurons. These results provide the first comprehensive description of the changes of CB(1), GABA(A) and GABA(B) receptor subunits in the HD basal ganglia. The upregulation of both GABA(A) and GABA(B) receptors may serve to increase the sensitivity of pallidal neurons to the decreased levels of GABA that occurs in the GP in HD. The loss of CB(1) receptors in HD is also thought to be a compensatory mechanism due to evidence that endocannabinoids modulate the reuptake of GABA in the GP. These findings show the high degree of plasticity of CB(1), GABA(A) and GABA(B) receptors and provide a better understanding of the GABAergic modulation of basal ganglia neurons in the normal and diseased human brain.
Allen
K L
KL
Department of Anatomy with Radiology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1023, New Zealand.
Waldvogel
H J
HJ
Glass
M
M
Faull
R L M
RL
D000368:Aged; D000369:Aged, 80 and over; D001931:Brain Mapping; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D015536:Down-Regulation / Q000502:physiology; D004745:Enkephalins / Q000032:analysis / Q000378:metabolism; D005260:Female; D005917:Globus Pallidus / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D007150:Immunohistochemistry; D008297:Male; D018613:Microscopy, Confocal; D008875:Middle Aged; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D009473:Neuronal Plasticity / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000032:analysis / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000032:analysis / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000032:analysis / Q000378:metabolism*; D013373:Substance P / Q000032:analysis / Q000378:metabolism; D015854:Up-Regulation / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D063385:Cannabinoid Receptor Modulators; D004745:Enkephalins; D043884:Receptor, Cannabinoid, CB1; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D013373:Substance P; D005680:gamma-Aminobutyric Acid